Page last updated: 2024-08-26

arsenic and Kahler Disease

arsenic has been researched along with Kahler Disease in 134 studies

Research

Studies (134)

Timeframe	Studies, this research(%)	All Research%
pre-1990	5 (3.73)	18.7374
1990's	1 (0.75)	18.2507
2000's	100 (74.63)	29.6817
2010's	28 (20.90)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Anderson, KC; Balaz, P; Bujnakova, Z; Cholujova, D; Dorfman, DM; Dutkova, E; Groen, RW; Hideshima, T; Jakubikova, J; Mitsiades, CS; Richardson, PG	1
Chao, NJ; de Castro, CM; Diehl, LF; Gasparetto, C; Gockerman, JP; Held, LA; Horwitz, ME; Long, GD; Moore, JO; Rizzieri, D	1
Chen, Z; Liu, P; Naranmandura, H; Rehman, K; Wang, WW; Xu, S; Zhang, M; Zhang, YF	1
Chen, B; Qian, W; Ye, B; Yu, Q; Zhang, X; Zhou, Y	1
Cernelc, P; Podgornik, H; Rebersek, K	1
Chen, XH; Qian, WB; Zhou, XJ; Zhou, YH	1
Černelč, P; Podgornik, H; Reberšek, K; Žontar, DM	1
Cui, JW; Elmahi, AY; Hao, SS; Li, D; Li, W; Niu, C; Wang, GJ	1
Boise, LH; Cai, Y; Liu, G; Matulis, S; Stice, S; Yehiayan, L	1
Wang, XN; Zhang, M	1
Fu, H; Shen, J; Wu, D	1
Wang, X; Zhang, M	1
Du, J; Fan, J; Fu, W; He, J; Hou, J; Li, R; Liu, S; Liu, X; Qu, Y; Xi, H; Yan, W; Yang, J; Zhang, C	1
Chen, Z; Ma, X; Shen, L; Yu, Y; Zhang, G; Zhou, L; Zhu, F; Zou, J	1
Chen, T; Chen, W; Deng, H; Jian, Y; Li, J; Shan, Z; Zeng, H; Zhang, J; Zhou, H	1
Che, FF; Cheng, J; Huang, XB; Shi, Y; Wang, CS; Wang, XD	1
Bonati, A; Cantoni, AM; Corradi, A; Costanzo, A; Giuliani, N; Levrero, M; Lombardi, G; Lunghi, P; Mazzera, L; Ricca, M; Riccioni, R; Rizzoli, V; Salvatore, L; Testa, U	1
Berenson, JR; Yellin, O	1
Dou, HJ; Hu, JP; Ren, ZH; Wang, MM; Zhu, Q; Zou, LF	2
Dahdaleh, FS; Musallam, KM; Shamseddine, AI; Taher, AT	1
Maiso, P; Mateos, MV; Ocio, EM; Pandiella, A; San-Miguel, JF	1
Alousi, A; Anderlini, P; Champlin, RE; Giralt, S; Hosing, C; Jones, RB; Khan, FB; Mendoza, F; Nieto, Y; Parikh, G; Pelosini, M; Popat, U; Qazilbash, MH; Saliba, RM; Wang, M; Weber, DM	1
Boise, LH; Cejas, PJ; Gutman, D; Lee, KP; Morales, AA	1
Ge, F; He, QY; Jin, L; Lu, XP; Xiong, S; Zeng, HL	1
Boise, LH; Cai, Y; Croutch, C; Gutman, D; Lee, KP; Matulis, SM; Morales, AA; Yehiayan, L	1
Illmer, T; Röllig, C	1
Ballon, DJ; Chang, CC; Chen, H; Feng, Y; Huang, W; Kamble, RT; Liao, B; Preti, HA; Rice, L; Wen, J; Zu, Y	1
Liang, Y; Xu, RZ; Zhang, L; Zhao, XY	1
Han, Y; Hou, J; Hu, X; Jiang, W; Meng, X; Shi, J; Tang, S; Tao, Y; Tricot, G; Wu, X; Wu, Y; Zangari, M; Zhan, F	1
Abeltino, M; Agnelli, L; Bolzoni, M; Bonomini, S; Colla, S; Giuliani, N; Neri, A; Rizzoli, V; Storti, P; Todoerti, K	1
Bashir, Q; Bassett, RL; Champlin, RE; Giralt, SA; Hosing, CM; Khan, H; Orlowski, RZ; Parmar, S; Popat, UR; Qazilbash, MH; Shah, JJ; Shah, N; Sharma, M; Thall, PF; Wang, M	1
Goel, A; Spitz, DR; Weiner, GJ	1
Esfahani, A; Gharamaleki, JV; Rezazadeh, M; Sanaat, Z; Ziae, JE	1
Du, J; Fu, W; Hou, J; Qu, X; Xi, H; Zhang, C; Zou, J	1
Hu, K; Ren, JJ; Song, YP; Xie, J; Zhang, M; Zhang, YJ	1
Chen, Y; Ge, QF; Lu, Y; Mu, QT; Ouyang, GF; Zhang, Y	1
Doudican, NA; Mazumder, A; Orlow, SJ; Wen, SY	1
Zhou, J	1
Boise, LH; Cai, Y; Lee, KP; Matulis, SM; Morales, AA; Yehiayan, L	1
Anderson, KC; Cole, CE; Ryoo, JJ	1
Anaissie, E; Badros, A; Barlogie, B; Desikan, R; Morris, C; Munshi, NC; Toor, A; Tricot, G; Zangari, M	1
Anderson, KC; Chauhan, D; Hideshima, T; Munshi, NC; Richardson, P	1
Dalton, WS	1
Bahlis, NJ; Boise, LH; Eckman, J; Fernandez, HF; Goodman, M; Jordan-McMurry, I; Kharfan-Dabaja, M; Lee, KP; McCafferty-Grad, J; Neil, J; Reis, I	1
Akiyama, M; Anderson, KC; Chauhan, D; Hayashi, T; Hideshima, T; Munshi, NC; Richardson, P; Schlossman, RL; Waxman, S	1
Anderson, KC; Hayashi, T; Hideshima, T	1
Gazitt, Y; Hilsenbeck, S; Liu, Q	1
Chen, YB; Ding, SQ; Fu, WJ; Hou, J; Kong, XT; Wang, DX; Yuan, ZG	2
D'Cruz, OJ; Liu, XP; Narla, RK; Uckun, FM	1
Gisslinger, H; Kees, M	1
Mehta, J; Pichardo, D; Rosen, S; Singhal, S	1
Almasan, A; Chen, J; Chen, Q; Jiang, C; Jin, H; Shi, Y; Tang, H; Tian, C; Zheng, Y	1
Brouet, JC; Chopin, M; Dosquet, C; Fermand, JP; Janin, A; Labaume, S; Larghero, J; Marolleau, JP; Poupon, J; Rousselot, P	1
Cohen, FJ; Gui, D; Ikezoe, T; Koeffler, HP; Kumagai, T; O'Kelly, J; Said, JW; Tong, XJ	1
Chen, SL	1
Gibson, AD; Klem, J; Price, N; Reddy, GK	1
Kaufman, J; Lonial, S	1
Ellison, R; Hussein, MA; Mason, J; Ravandi, F; Rifkin, RM; Saleh, M	1
Li, JQ; Li, Y; Shi, YJ; Wu, SL	1
Guo, ZX; Jin, J	1
Bertola, A; Boccadoro, M; Bruno, B; Giaccone, L; Massaia, M; Palumbo, A; Rotta, M	1
Ravandi, F	1
Arnulf, B; Chevret, S; Cimerman, P; Claude Brouet, J; Dombret, H; Hermine, O; Larghero, J; Madelaine-Chambrin, I; Paul Fermand, J; Poupon, J; Rousselot, P; Royer, B; Tibi, A	1
Berenson, JR; Ferretti, D; Purner, MB; Swift, RA	1
Berenson, JR; Borad, MJ; Swift, R	1
Cardinale, G; Gervasi, F; Pagnucco, G	1
Chen, SJ; Chen, Z; Dong, Y; Fang, J; Hu, J	1
Comenzo, RL; Kalakonda, N; Zhou, P	1
Gao, WR; Hou, J	1
Chng, WJ; Lau, LG; Mow, BM; Yusof, N	1
Chen, QB; Gao, WR; Hou, J; Xiong, H	1
Chen, SL; Chen, WM; Li, CL; Liu, JZ; Xiao, B; Zhang, HB	1
Fu, HY; Shen, JZ	1
Anderson, KC; Catley, L; Chauhan, D; Tai, YT	1
Ikeda, Y; Ito, K; Kizaki, M; Nakazato, T	1
Saunders, G	1
Murakami, H	1
Ahn, E; Bach, A; Bouzari, N; Chen, H; Nouri, K; Ricotti, CA	1
Anderson, KC; Hideshima, T; Richardson, PG; Schlossman, R	1
Liu, PB; Liu, SX; Wang, MC	3
Liu, T; Meng, WT; Tan, J; Yu, J; Zhu, HL	1
Hess, U	1
He, W; Hu, Y; Sun, C; Wang, Y; Zhang, X	1
Abou-Jawde, RM; Andresen, S; Baz, R; Hussein, M; Karam, MA; Kelly, M; Reed, J; Walker, E	1
Emi, N; Iida, S; Kajiguchi, T; Naoe, T; Ueda, R; Yamamoto, K	1
Hussein, MA; Kalmadi, SR	1
Berenson, JR; Bessudo, A; Boccia, R; Bozdech, M; Ferretti, D; Flam, M; Jilani, S; Louie, R; Lutzky, J; Moss, R; Patel, R; Russell, K; Siegel, D; Stadtmauer, E; Steis, R; Swift, RA; Talisman Pomeroy, J; Volk, J; Wong, SF; Yeh, HS	1
Ackerstein, A; Bitan, M; Gesundheit, B; Or, R; Resnik, IB; Shapira, MY	1
Amadori, S; Beksac, M; Sonneveld, P; van Droogenbroeck, J; Wu, KL; Zweegman, S	1
Bonati, A; Lunghi, P; Rizzoli, V	1
Berenson, JR; Yeh, HS	1
Berenson, JR; Mapes, R; Matous, J; Morrison, B; Swift, RA; Yeh, HS	1
Fu, HY; Sheng, JZ; Sheng, SF; Zhou, HR	1
Baritaki, S; Berenson, JR; Bonavida, B; Campbell, RA; Chen, H; Gordon, M; Pang, S; Said, J; Sanchez, E; Shalitin, D; Steinberg, JA; Wang, C	1
Falnoga, I; Podgornik, H; Pucer, A; Slejkovec, Z; Tusek-Znidaric, M	1
Meng, H; Qian, W; Shao, K; Yang, C; Yang, X; Ye, X; Zhou, Y	1
Feng, TM; Tan, LJ; Wang, W; Wei, QF; Yang, BF; Zhou, J	1
Huang, HB; Yu, QH; Zhan, R	1
Takatoku, M	1
Benson, DM; Denlinger, N; Farag, SS; Hofmeister, CC; Jansak, B; Kraut, EH	1
Fei, XM; Ge, Z; Li, JY; Lin, RF; Liu, P; Lu, H; Shen, WY; Wang, YR; Wu, YJ; Zhang, JF	1
Cernelc, P; Falnoga, I; Goessler, W; Podgornik, H; Raml, R; Slejkovec, Z; van Elteren, JT	1
Ballon, DJ; Chang, CC; Cheng, HY; Feng, Y; Huang, J; Liu, S; Mo, A; Rice, L; Wen, J; Zu, Y	1
Liu, P; Liu, S; Wang, M	1
Fu, WJ; Hou, J; Wang, DX; Yuan, ZG; Zhou, LL	1
Boise, LH; Gutman, D; Lee, KP; Morales, AA	1
Fu, W; Hou, J; Jiang, H; Wang, D; Yuan, Z; Zhou, L	1
Brouet, JC; Fermand, JP; Labaume, S; Larghero, J; Marolleau, JP; Noguera, MH; Rousselot, P	1
Cheson, BD; McBee, WL; Murgo, AJ	1
Hyun, JM; Jung, CW; Kim, BK; Kim, ES; Lee, CC; Lee, YY; Park, WH; Seol, JG	1
Gallagher, RE	1
Arnulfo, A; Baj, G; Canella, D; Deaglio, S; Malavasi, F; Waxman, S	1
Munshi, NC	1
Bahlis, NJ; Boise, LH; Dalton, WS; Grad, JM; Oshiro, MM; Reis, I	1
Cai, X; Chen, G; Chen, S; Huang, X; Jia, P; Shen, Y; Wang, L; Wang, Z; Yang, J; Yu, Y; Zhang, X; Zhou, L; Zhou, Y	1
Cai, X; Huang, X; Zhou, Y	1
Hussein, MA; Juturi, JV; Lieberman, I	1
Gartenhaus, RB; Gordon, LI; Li, Y; Paniaqua, M; Prachand, SN	1
Hussein, MA	2
Bloomfield, CD; Slack, JL; Tallman, MS; Tricot, G; Waxman, S	1
Miller, WH	1
Chen, GQ; Chen, SJ; Chen, Z; Shen, ZX; Sun, GL; Tong, JH; Wang, ZY	1
Iso, N; Williams, JW	1
Franklin, EC; Yoo, TJ	1
Danieli, G	1
BIRCHALL, R; CHRISTIANSON, HB	1
Bajenova, O; Childs, BH; Feinman, R; Michaeli, J; Pearse, R; Tang, B	1
Grünwald, HW; Rosner, F	1

Reviews

34 review(s) available for arsenic and Kahler Disease

Article	Year
New drugs in multiple myeloma. Current opinion in supportive and palliative care, 2008, Volume: 2, Issue:3 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide	2008
Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. Thrombosis research, 2009, Volume: 123, Issue:5 Topics: Arsenic Trioxide; Arsenicals; Aspirin; Boronic Acids; Bortezomib; Heparin, Low-Molecular-Weight; Humans; Incidence; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide; Venous Thromboembolism	2009
New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. The Lancet. Oncology, 2008, Volume: 9, Issue:12 Topics: Antibodies, Monoclonal; Antigens, Surface; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cysteine Proteinase Inhibitors; Depsipeptides; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Farnesyl-Diphosphate Farnesyltransferase; Heat-Shock Proteins; Histone Deacetylase Inhibitors; Humans; Mitogen-Activated Protein Kinase Kinases; Multiple Myeloma; NF-kappa B; Oligopeptides; Oxides; Peptides, Cyclic; Phosphoinositide-3 Kinase Inhibitors; Protein Kinases; Receptor Protein-Tyrosine Kinases; Receptors, Cell Surface; Signal Transduction; TOR Serine-Threonine Kinases	2008
The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: a systematic review. Cancer treatment reviews, 2009, Volume: 35, Issue:5 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Oxides; Treatment Outcome	2009
Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma. Journal of cellular biochemistry, 2012, Volume: 113, Issue:2 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lymphoma, B-Cell; Multiple Myeloma; Oxidation-Reduction; Oxidative Stress; Oxides; Pyrazines; Radiotherapy	2012
Arsenic trioxide: an ancient drug revived. Chinese medical journal, 2012, Volume: 125, Issue:19 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Oxides; Reactive Oxygen Species	2012
Novel therapies for multiple myeloma. Blood reviews, 2002, Volume: 16, Issue:3 Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cysteine Endopeptidases; Enzyme Inhibitors; Estradiol; Humans; Multienzyme Complexes; Multiple Myeloma; Oxides; Proteasome Endopeptidase Complex; Thalidomide; Tissue Extracts	2002
Novel biologically based therapies for multiple myeloma. International journal of hematology, 2002, Volume: 76 Suppl 1 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Multiple Myeloma; Oxides; Protease Inhibitors	2002
Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: N. J. Bahlis et al., Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of re Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:12 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Clinical Trials as Topic; Drug Combinations; Glutathione; Humans; Mitochondria; Multiple Myeloma; Oxides; Reactive Oxygen Species	2002
Novel therapies for multiple myeloma. British journal of haematology, 2003, Volume: 120, Issue:1 Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Enzyme Inhibitors; Estradiol; Heterocyclic Compounds, 3-Ring; Humans; Multiple Myeloma; NF-kappa B; Oxides; Phthalazines; Protease Inhibitors; Protein-Tyrosine Kinases; Pyridines; Thalidomide	2003
Therapy strategies for multiple myeloma: current status. Wiener klinische Wochenschrift, 2003, Aug-14, Volume: 115, Issue:13-14 Topics: Adjuvants, Immunologic; Aged; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Diphosphonates; Drug Therapy, Combination; Erythropoietin; Glucocorticoids; Growth Inhibitors; Humans; Immunosuppressive Agents; Middle Aged; Multiple Myeloma; Oxides; Peripheral Blood Stem Cell Transplantation; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Transplantation, Homologous	2003
Recent developments and future directions in the treatment of multiple myeloma. Cancer biotherapy & radiopharmaceuticals, 2003, Volume: 18, Issue:4 Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Clinical Trials as Topic; Cysteine Endopeptidases; Diphosphonates; Doxorubicin; Erythropoietin; Etoposide; Forecasting; Humans; Interferons; Multienzyme Complexes; Multiple Myeloma; Organometallic Compounds; Organophosphorus Compounds; Oxides; Peripheral Blood Stem Cell Transplantation; Proteasome Endopeptidase Complex; Thalidomide; Tissue Extracts	2003
Multiple myeloma: the role of transplant and novel treatment strategies. Seminars in oncology, 2004, Volume: 31, Issue:2 Suppl 4 Topics: Adjuvants, Immunologic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Oxides; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous	2004
New drugs for treatment of multiple myeloma. The Lancet. Oncology, 2004, Volume: 5, Issue:7 Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Diphosphonates; Enzyme Inhibitors; Estradiol; Humans; Multiple Myeloma; Neovascularization, Pathologic; Oxides; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Thalidomide	2004
Targeting multiple myeloma cells and their bone marrow microenvironment. Annals of the New York Academy of Sciences, 2004, Volume: 1028 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion; Cytokines; Disease Progression; Disease-Free Survival; Humans; Ligands; Multiple Myeloma; Neovascularization, Pathologic; Oxides; Protease Inhibitors; Pyrazines; Signal Transduction; Thalidomide	2004
Arsenic in cancer therapy. Anti-cancer drugs, 2005, Volume: 16, Issue:2 Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenicals; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Leukemia; Lymphoma; Multiple Myeloma	2005
Targeted therapy in multiple myeloma. Cancer control : journal of the Moffitt Cancer Center, 2005, Volume: 12, Issue:2 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; DNA, Antisense; Drug Delivery Systems; Farnesyltranstransferase; Humans; Immunosuppressive Agents; Lovastatin; Multiple Myeloma; Oxides; Protease Inhibitors; Pyrazines; Thalidomide	2005
Perspectives for combination therapy to overcome drug-resistant multiple myeloma. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2005, Volume: 8, Issue:4 Topics: 2-Methoxyestradiol; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estradiol; Histone Deacetylase Inhibitors; Humans; Multiple Myeloma; Oxides; p38 Mitogen-Activated Protein Kinases; Proteasome Inhibitors; Receptor Protein-Tyrosine Kinases; Thalidomide	2005
Overview of drug therapy for multiple myeloma. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2005, Volume: 11, Issue:3 Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Myeloma Proteins; Oxides; Pyrazines; Thalidomide	2005
[New strategy for the treatment of multiple myeloma]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2005, Volume: 46, Issue:12 Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Dexamethasone; Drug Design; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Oxides; Prognosis; Protease Inhibitors; Purines; Pyrazines; Roscovitine; Thalidomide; Transplantation Conditioning	2005
New treatments for multiple myeloma. Oncology (Williston Park, N.Y.), 2005, Volume: 19, Issue:14 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Oxides; Pyrazines; Thalidomide	2005
[The plasma cell myeloma--molecular pathogenesis and target therapies]. Therapeutische Umschau. Revue therapeutique, 2006, Volume: 63, Issue:4 Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Communication; Chromosome Aberrations; Gene Expression; Glycoproteins; Growth Inhibitors; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Osteoporosis; Osteoprotegerin; Oxides; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Thalidomide; Time Factors	2006
The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma. Acta haematologica, 2006, Volume: 116, Issue:1 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; History, 18th Century; History, 20th Century; History, 21st Century; History, Ancient; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide	2006
Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug. Current pharmaceutical biotechnology, 2006, Volume: 7, Issue:6 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Multiple Myeloma; Oxides; Practice Patterns, Physicians'; Treatment Outcome	2006
Arsenic compounds in the treatment of multiple myeloma: a new role for a historical remedy. Clinical lymphoma & myeloma, 2006, Volume: 7, Issue:3 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Screening Assays, Antitumor; History, 18th Century; Humans; Medical Oncology; Models, Biological; Multiple Myeloma; Oxides	2006
[Molecular targeting therapy for multiple myeloma]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Volume: 65, Issue:12 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bevacizumab; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Oxides; Protease Inhibitors; Pyrazines; Thalidomide; TNF-Related Apoptosis-Inducing Ligand; Vascular Endothelial Growth Factor A	2007
Arsenic trioxide: an emerging therapy for multiple myeloma. The oncologist, 2001, Volume: 6 Suppl 2 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Multiple Myeloma; Oxides; Prognosis	2001
Multiple myeloma: present and future. Current opinion in oncology, 2002, Volume: 14, Issue:1 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Oxides; Pamidronate; Thalidomide; Zoledronic Acid	2002
Arsenic trioxide: a new immunomodulatory agent in the management of multiple myeloma. Medical oncology (Northwood, London, England), 2001, Volume: 18, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Humans; Immunologic Factors; Multiple Myeloma; Oxides	2001
Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide. The oncologist, 2002, Volume: 7 Suppl 1 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Oxides; Recurrence; Remission Induction; Survival Analysis; Treatment Outcome; Tretinoin	2002
Molecular targets of arsenic trioxide in malignant cells. The oncologist, 2002, Volume: 7 Suppl 1 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Glutathione; Growth Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Oxides	2002
Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma. The oncologist, 2002, Volume: 7 Suppl 1 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Adhesion Molecules; Cytokines; Humans; Multiple Myeloma; Neovascularization, Pathologic; Oxides; Pyrazines; Thalidomide; Treatment Outcome	2002
Expanding the use of arsenic trioxide: leukemias and beyond. Seminars in hematology, 2002, Volume: 39, Issue:2 Suppl 1 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Neoplasms; Oxides	2002
Cytotoxic drugs and leukaemogenesis. Clinics in haematology, 1980, Volume: 9, Issue:3 Topics: Adult; Aged; Arsenic; Benzene; Bone Marrow; Breast Neoplasms; Female; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Male; Melphalan; Middle Aged; Multiple Myeloma; Mycosis Fungoides; Ovarian Neoplasms; Paraproteinemias; Waldenstrom Macroglobulinemia	1980

Trials

13 trial(s) available for arsenic and Kahler Disease

Article	Year
A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma. Cancer investigation, 2013, Volume: 31, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oxides; Pyrazines; Recurrence	2013
Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Antioxidants; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Oxides; Survival Rate; Time Factors; Transplantation Conditioning; Transplantation, Autologous	2008
A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer, 2012, May-01, Volume: 118, Issue:9 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Blood Transfusion, Autologous; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Oxides; Prognosis; Pyrazines; Transplantation Conditioning	2012
Arsenic trioxide in patients with refractory multiple myeloma: a prospective, phase II, single-arm study. Acta medica Iranica, 2011, Volume: 49, Issue:8 Topics: Adult; Aged; Arsenic Trioxide; Arsenicals; Female; Humans; Interleukin-6; Male; Middle Aged; Multiple Myeloma; Oxides; Prospective Studies; Treatment Outcome; Vascular Endothelial Growth Factor A	2011
Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia, 2002, Volume: 16, Issue:9 Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Evaluation; Humans; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Oxides; Salvage Therapy; Treatment Outcome	2002
Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Drug Resistance, Neoplasm; Feasibility Studies; Female; Glutathione; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oxides; Salvage Therapy; Treatment Outcome	2002
Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. British journal of haematology, 2004, Volume: 125, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Oxides; Salvage Therapy; Treatment Outcome	2004
A prospective, open-label safety and efficacy study of combination treatment with melphalan, arsenic trioxide, and ascorbic acid in patients with relapsed or refractory multiple myeloma. Clinical lymphoma, 2004, Volume: 5, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Disease Progression; Drug Resistance, Neoplasm; Humans; Melphalan; Middle Aged; Multiple Myeloma; Oxides; Prospective Studies; Recurrence; Time Factors; Treatment Outcome	2004
Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial. Medical oncology (Northwood, London, England), 2006, Volume: 23, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oxides; Recurrence; Vitamins	2006
Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. British journal of haematology, 2006, Volume: 135, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Creatinine; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Oxides; Prospective Studies; Recurrence; Survival Analysis; Treatment Outcome	2006
Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma. Haematologica, 2006, Volume: 91, Issue:12 Topics: Adult; Aged; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Dexamethasone; Drug Therapy, Combination; Follow-Up Studies; Humans; Middle Aged; Multiple Myeloma; Oxides; Recurrence	2006
A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Mar-15, Volume: 13, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oxides; Pyrazines; Recurrence; Survival Analysis; Treatment Failure; Treatment Outcome	2007
Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma. Leukemia research, 2008, Volume: 32, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Dexamethasone; Doxorubicin; Drug Evaluation; Humans; Middle Aged; Multiple Myeloma; Oxides; Treatment Outcome; Vincristine	2008

Other Studies

87 other study(ies) available for arsenic and Kahler Disease

Article	Year
Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma. British journal of haematology, 2017, Volume: 179, Issue:5 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Death; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Delivery Systems; Humans; Mice, SCID; Molecular Targeted Therapy; Multiple Myeloma; Nanoparticles; Neoplastic Stem Cells; Oxides; Prohibitins; Sulfides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2017
Anticancer activity in human multiple myeloma U266 cells: synergy between cryptotanshinone and arsenic trioxide. Metallomics : integrated biometal science, 2013, Volume: 5, Issue:7 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Drug Synergism; Humans; Multiple Myeloma; Oxides; Phenanthrenes	2013
Arsenic trioxide-enhanced, matrine-induced apoptosis in multiple myeloma cell lines. Planta medica, 2013, Volume: 79, Issue:9 Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Bcl-2-Like Protein 11; Caspase 3; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Inhibitor of Apoptosis Proteins; Inhibitory Concentration 50; Matrines; Medicine, Chinese Traditional; Membrane Proteins; Multiple Myeloma; Oxides; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinolizines; Survivin	2013
Evaluation of multiple myeloma cell apoptosis in primary bone marrow samples. Clinical laboratory, 2013, Volume: 59, Issue:3-4 Topics: ADP-ribosyl Cyclase 1; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Marrow; Camptothecin; Female; Flow Cytometry; Humans; Immunophenotyping; Male; Multiple Myeloma; Oxides; Syndecan-1	2013
[Homoharringtonine combined arsenic trioxide induced apoptosis in human multiple myeloma cell line RPMI 8226: an experimental research]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2013, Volume: 33, Issue:6 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Caspase 3; Caspase 9; Cell Line, Tumor; Harringtonines; Homoharringtonine; Humans; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Oxides; Phosphorylation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2	2013
Selective apoptosis of multiple myeloma cells in primary samples induced by arsenic trioxide. Hematology (Amsterdam, Netherlands), 2014, Volume: 19, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Marrow; Cells, Cultured; Female; Humans; Male; Multiple Myeloma; Oxides	2014
Effects of arsenic trioxide alone and in combination with bortezomib in multiple myeloma RPMI 8266 cells. Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; G2 Phase Cell Cycle Checkpoints; Humans; Multiple Myeloma; Oxides; Proto-Oncogene Proteins c-bcl-2; Pyrazines	2013
Dimethylarsinothioyl glutathione as a metabolite in human multiple myeloma cell lines upon exposure to Darinaparsin. Chemical research in toxicology, 2014, May-19, Volume: 27, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Arsenicals; Cell Line, Tumor; Glutathione; Humans; Multiple Myeloma	2014
[Apoptosis-inducing effect of valproic acid combined with arsenic trioxide on RPMI 8226 cells and its mechanism]. Zhongguo shi yan xue ye xue za zhi, 2014, Volume: 22, Issue:4 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Multiple Myeloma; Oxides; Proto-Oncogene Proteins c-bcl-2; Valproic Acid	2014
[Hypermethylation of CpG island of DLC-1 gene and arsenic trioxide-induced DLC-1 gene demethylation in multiple myeloma]. Zhonghua yi xue za zhi, 2014, Sep-30, Volume: 94, Issue:36 Topics: Arsenic Trioxide; Arsenicals; Cell Line, Tumor; CpG Islands; DNA Methylation; GTPase-Activating Proteins; Humans; Multiple Myeloma; Oxides; RNA, Messenger; Tumor Suppressor Proteins	2014
Synergistic effects of valproic acid and arsenic trioxide on RPMI8226 cells in vitro and the possible underlying mechanisms. Molecular medicine reports, 2015, Volume: 12, Issue:1 Topics: Acetylation; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Gene Expression Regulation, Neoplastic; Histone Deacetylase 1; Humans; Multiple Myeloma; Oxides; Proto-Oncogene Proteins c-bcl-2; Valproic Acid	2015
MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma. Oncotarget, 2015, Jun-20, Volume: 6, Issue:17 Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzopyrans; Blotting, Western; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Melphalan; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Multiple Myeloma; Neoplastic Stem Cells; Oxides; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; Side-Population Cells; Signal Transduction; TOR Serine-Threonine Kinases; Transplantation, Heterologous; Tuberous Sclerosis	2015
Evaluation of the change in sphingolipids in the human multiple myeloma cell line U266 and gastric cancer cell line MGC-803 treated with arsenic trioxide. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2015, Nov-01, Volume: 1004 Topics: Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Chromatography, High Pressure Liquid; Humans; Multiple Myeloma; Oxides; Spectrometry, Mass, Electrospray Ionization; Sphingolipids; Stomach Neoplasms; Tandem Mass Spectrometry	2015
Effects and mechanism of arsenic trioxide in combination with rmhTRAIL in multiple myeloma. Experimental hematology, 2016, Volume: 44, Issue:2 Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Chromatography, High Pressure Liquid; Mass Spectrometry; Multiple Myeloma; Oxides; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand	2016
[Synergistic Inhibitory Effect of Arsenic Trioxide Combined with Itraconazole on Hedgehog Pathway of Multiple Myeloma NCI-H929 Cells]. Zhongguo shi yan xue ye xue za zhi, 2016, Volume: 24, Issue:5 Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Hedgehog Proteins; Humans; Itraconazole; Mice; Multiple Myeloma; Oxides; Signal Transduction	2016
Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood, 2008, Sep-15, Volume: 112, Issue:6 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Diphenylamine; Humans; MAP Kinase Signaling System; Mice; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Multiple Myeloma; Oxides; Protein Kinase Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2008
[Arsenic trioxide induces socs-1 gene demethylation in myeloma cell lines]. Zhongguo shi yan xue ye xue za zhi, 2008, Volume: 16, Issue:5 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; CpG Islands; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Oxides; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling Proteins	2008
[Correlation of cell cycle alteration to SOCS-1 gene demethylation induced by arsenic trioxide in myeloma cell lines]. Ai zheng = Aizheng = Chinese journal of cancer, 2008, Volume: 27, Issue:11 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Methylation; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Oxides; RNA, Messenger; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling Proteins	2008
Reactive oxygen species are not required for an arsenic trioxide-induced antioxidant response or apoptosis. The Journal of biological chemistry, 2009, May-08, Volume: 284, Issue:19 Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Butylated Hydroxyanisole; Gene Expression Profiling; Growth Inhibitors; Heme Oxygenase-1; Humans; Multiple Myeloma; NF-E2-Related Factor 2; Oligonucleotide Array Sequence Analysis; Oxidative Stress; Oxides; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Subcellular Fractions	2009
Proteomic and functional analyses reveal a dual molecular mechanism underlying arsenic-induced apoptosis in human multiple myeloma cells. Journal of proteome research, 2009, Volume: 8, Issue:6 Topics: 14-3-3 Proteins; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Electrophoresis, Gel, Two-Dimensional; Gene Knockdown Techniques; HSP90 Heat-Shock Proteins; Humans; Multiple Myeloma; Oxides; Protein Interaction Mapping; Proteome; Proteomics; RNA, Small Interfering; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Stress, Physiological; Ubiquitin-Protein Ligase Complexes	2009
Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line. Molecular cancer therapeutics, 2009, Volume: 8, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Line, Tumor; Cell Survival; Cysteine; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glutathione; Humans; Multiple Myeloma; Oxides	2009
Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition. Leukemia research, 2010, Volume: 34, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Drug Synergism; Enzyme Activation; HSP27 Heat-Shock Proteins; Humans; Multiple Myeloma; Oxides; p38 Mitogen-Activated Protein Kinases; Pyrazines; STAT3 Transcription Factor	2010
Berbamine, a novel nuclear factor kappaB inhibitor, inhibits growth and induces apoptosis in human myeloma cells. Acta pharmacologica Sinica, 2009, Volume: 30, Issue:12 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzylisoquinolines; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Dexamethasone; DNA-Binding Proteins; Doxorubicin; G1 Phase; Humans; I-kappa B Kinase; Intracellular Signaling Peptides and Proteins; Multiple Myeloma; NF-kappa B; Nuclear Proteins; Oxides; Plasma Cells; Signal Transduction; Tumor Necrosis Factor alpha-Induced Protein 3	2009
Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2. Cancer biology & therapy, 2010, Dec-01, Volume: 10, Issue:11 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Growth Processes; Cell Survival; Down-Regulation; Humans; Interferon Regulatory Factor-1; Multiple Myeloma; Oxides; Receptors, TNF-Related Apoptosis-Inducing Ligand; Recombinant Proteins; RNA, Messenger; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand	2010
The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Experimental hematology, 2011, Volume: 39, Issue:1 Topics: Aged; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Oxides; Polymerase Chain Reaction; Pyrazines; Zoledronic Acid	2011
Arsenic trioxide exerts antimyeloma effects by inhibiting activity in the cytoplasmic substrates of histone deacetylase 6. PloS one, 2012, Volume: 7, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Cytoplasm; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; HSP90 Heat-Shock Proteins; Humans; I-kappa B Kinase; Immunoprecipitation; Multiple Myeloma; Oxides; Phosphorylation; Signal Transduction; Tubulin	2012
[Caspase-independent apoptosis induced by arsenic trioxide in human multiple myeloma cell RPMI8226]. Zhongguo shi yan xue ye xue za zhi, 2012, Volume: 20, Issue:1 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Line, Tumor; Humans; Multiple Myeloma; Oxides; Proto-Oncogene Proteins c-bcl-2	2012
Effects of arsenic trioxide combined with bortezomib on apoptosis of multiple myeloma cell line KM3 and its mechanisms. Zhongguo shi yan xue ye xue za zhi, 2012, Volume: 20, Issue:1 Topics: Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Bcl-2-Like Protein 11; bcl-X Protein; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Humans; Membrane Proteins; Multiple Myeloma; Oxides; Proto-Oncogene Proteins; Pyrazines	2012
Sulforaphane synergistically enhances the cytotoxicity of arsenic trioxide in multiple myeloma cells via stress-mediated pathways. Oncology reports, 2012, Volume: 28, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases, Initiator; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Drug Synergism; eIF-2 Kinase; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Eukaryotic Initiation Factor-2; Glutathione; HSP90 Heat-Shock Proteins; Humans; I-kappa B Kinase; Isothiocyanates; Multiple Myeloma; Oxides; Phosphorylation; Poly(ADP-ribose) Polymerases; Reactive Oxygen Species; Regulatory Factor X Transcription Factors; Signal Transduction; Sulfoxides; Thiocyanates; Transcription Factors; Tumor Necrosis Factor-alpha; Unfolded Protein Response; X-Box Binding Protein 1	2012
Alterations in glutathione levels and apoptotic regulators are associated with acquisition of arsenic trioxide resistance in multiple myeloma. PloS one, 2012, Volume: 7, Issue:12 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Glutathione; Humans; Melphalan; Minor Histocompatibility Antigens; Multiple Myeloma; Oxides; Phenotype; Proto-Oncogene Proteins c-bcl-2	2012
Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Molecular cancer therapeutics, 2002, Volume: 1, Issue:10 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Caspase 9; Caspases; Cell Adhesion; Cell Division; Cell Nucleus; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance; Endothelial Growth Factors; Enzyme Activation; Flow Cytometry; Growth Inhibitors; Humans; Intercellular Signaling Peptides and Proteins; Interleukin-6; Lymphokines; Multiple Myeloma; Oxides; Signal Transduction; STAT3 Transcription Factor; Time Factors; Trans-Activators; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2002
Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood, 2003, May-15, Volume: 101, Issue:10 Topics: Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Caspase 8; Caspase 9; Caspases; Cell Cycle; Cysteine Proteinase Inhibitors; Enzyme Activation; Fluorescent Antibody Technique; G1 Phase; G2 Phase; Growth Inhibitors; Humans; Kinetics; Membrane Glycoproteins; Mitosis; Multiple Myeloma; Mutagenesis; Oxides; Poly(ADP-ribose) Polymerases; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53	2003
[Effects of arsenic trioxide on cell cycle and expression of cyclin dependent kinase inhibitors of multiple myeloma cells]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2003, Volume: 24, Issue:4 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Cycle; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Humans; Multiple Myeloma; Oxides; RNA, Messenger; Tumor Cells, Cultured	2003
Phenylarsonic acid compounds with broad-spectrum and potent cytotoxic activity against human cancer cells. Arzneimittel-Forschung, 2003, Volume: 53, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Arsenicals; Cell Division; Female; Flow Cytometry; Humans; In Situ Nick-End Labeling; Male; Microscopy, Confocal; Multiple Myeloma; Neoplasm Transplantation; Neoplasms; Ovarian Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Structure-Activity Relationship; Testicular Neoplasms; Tumor Cells, Cultured	2003
Essential role of the voltage-dependent anion channel (VDAC) in mitochondrial permeability transition pore opening and cytochrome c release induced by arsenic trioxide. Oncogene, 2004, Feb-12, Volume: 23, Issue:6 Topics: Animals; Annexin A5; Arsenic Trioxide; Arsenicals; Cytochromes c; Flow Cytometry; Humans; Intracellular Membranes; Ion Channel Gating; Membrane Potentials; Mice; Mice, Inbred BALB C; Mitochondria; Mitochondria, Liver; Multiple Myeloma; Oxides; Permeability; Porins; Proteolipids; Tumor Cells, Cultured; Voltage-Dependent Anion Channels	2004
[Mechanism of arsenic trioxide-induced cytotoxicity on multiple myeloma cells]. Ai zheng = Aizheng = Chinese journal of cancer, 2003, Volume: 22, Issue:12 Topics: Acetylcysteine; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Division; Cell Survival; Drug Interactions; Glutathione; Humans; Multiple Myeloma; Oxides; Tumor Cells, Cultured; Vitamin K 3	2003
Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice. European journal of haematology, 2004, Volume: 72, Issue:3 Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Division; Humans; Immunoglobulin G; Melarsoprol; Mice; Mice, SCID; Multiple Myeloma; Neoplasm Transplantation; Neoplasms, Experimental; Oxides; Plasma Cells; Receptors, Interleukin-6; Survival Analysis; Tissue Distribution; Xenograft Model Antitumor Assays	2004
RWJ-241947 (MCC-555), a unique peroxisome proliferator-activated receptor-gamma ligand with antitumor activity against human prostate cancer in vitro and in beige/nude/ X-linked immunodeficient mice and enhancement of apoptosis in myeloma cells induced by Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Feb-15, Volume: 10, Issue:4 Topics: Agar; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Caspases; CD36 Antigens; Cell Cycle; Cell Differentiation; Cell Division; Cell Line, Tumor; Cell Survival; Genetic Linkage; Humans; Immunologic Deficiency Syndromes; Ligands; Luciferases; Male; Mice; Multiple Myeloma; Oxides; Prostatic Neoplasms; Receptors, Cytoplasmic and Nuclear; Tetrazolium Salts; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Transfection; U937 Cells; X Chromosome	2004
[Targeted in therapies multiple myeloma]. Zhonghua nei ke za zhi, 2004, Volume: 43, Issue:2 Topics: Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Multiple Myeloma; Oxides; Pyrazines; Thalidomide	2004
45th Annual Meeting of the American Society of Hematology December 6-9, 2003. Clinical lymphoma, 2004, Volume: 4, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Hematology; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multicenter Studies as Topic; Multiple Myeloma; Oxides; Prognosis; Protein-Tyrosine Kinases; Recurrence; Risk; Rituximab; Salvage Therapy; Thalidomide; Time Factors; ZAP-70 Protein-Tyrosine Kinase	2004
[Re-expression of p16 gene in myeloma cell line U266 by arsenic trioxide]. Ai zheng = Aizheng = Chinese journal of cancer, 2004, Volume: 23, Issue:6 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; DNA Methylation; DNA Methyltransferase 3A; DNA, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, p16; Humans; Multiple Myeloma; Oxides; RNA, Messenger	2004
[Effect of arsenic trioxide on telomerase and telomerase reverse transcriptase in KM3 cell line]. Zhongguo shi yan xue ye xue za zhi, 2004, Volume: 12, Issue:3 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Line, Tumor; DNA-Binding Proteins; Humans; Multiple Myeloma; Oxides; RNA, Messenger; Telomerase	2004
Arsenic trioxide: expanding roles for an ancient drug? Leukemia, 2004, Volume: 18, Issue:9 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Oxides; Salvage Therapy	2004
A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients. Leukemia, 2004, Volume: 18, Issue:9 Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oxides; Salvage Therapy	2004
Nursing considerations for nontraditional treatment approaches to hematologic malignancies. ONS news, 2004, Volume: 19, Issue:9 Suppl Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Nurse's Role; Oncology Nursing; Oxides; Treatment Outcome	2004
Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma. Leukemia, 2005, Volume: 19, Issue:1 Topics: Aged; Antineoplastic Agents, Alkylating; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Oxides; Recurrence; Treatment Outcome	2005
Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. British journal of haematology, 2005, Volume: 128, Issue:5 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; DNA Fingerprinting; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Multiple Myeloma; Oxides; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; Superoxides	2005
[Effect of 2-methoxyestradiol on proliferation and apoptosis of myeloma cell lines]. Zhongguo shi yan xue ye xue za zhi, 2005, Volume: 13, Issue:2 Topics: 2-Methoxyestradiol; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Proliferation; Dexamethasone; Dose-Response Relationship, Drug; Drug Synergism; Estradiol; Humans; Multiple Myeloma; Oxides; Time Factors; Tumor Cells, Cultured	2005
[Investigation of the effect of 2-methoxyestradiol and arsenic trioxide on the apoptosis-associated gene expression profile of myeloma cells]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2005, Volume: 26, Issue:4 Topics: 2-Methoxyestradiol; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Estradiol; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Oxides; Reverse Transcriptase Polymerase Chain Reaction; Tubulin Modulators	2005
[Detection of gene expression alteration of myeloma cells treated with arsenic trioxide]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2005, Volume: 26, Issue:4 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Library; Humans; Multiple Myeloma; Oxides; Plasmids; Transformation, Bacterial	2005
[Hypermethylation of CpG island of p16 gene and arsenic trioxide induced p16 gene demethylation in multiple myeloma]. Zhonghua nei ke za zhi, 2005, Volume: 44, Issue:6 Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; CpG Islands; Cyclin-Dependent Kinase Inhibitor p16; DNA Methylation; Female; Genes, p16; Humans; Male; Middle Aged; Multiple Myeloma; Oxides; RNA, Messenger	2005
Green tea component, catechin, induces apoptosis of human malignant B cells via production of reactive oxygen species. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Aug-15, Volume: 11, Issue:16 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; B-Lymphocytes; bcl-2-Associated X Protein; Caspase 3; Caspases; Catechin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Intracellular Membranes; Membrane Potentials; Mitochondria; Multiple Myeloma; Oxides; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Signal Transduction; Tea; Time Factors	2005
The incidence of recurrent herpes simplex and herpes zoster infection during treatment with arsenic trioxide. Journal of drugs in dermatology : JDD, 2006, Volume: 5, Issue:2 Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Colonic Neoplasms; Female; Herpes Simplex; Herpes Zoster; Humans; Male; Multiple Myeloma; Oxides; Recurrence	2006
[Changes of gene expression profile of multiple myeloma cell line RPMI 8226 treated by arsenic trioxide]. Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine, 2006, Volume: 4, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Gene Expression Profiling; Humans; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Oxides; Tumor Cells, Cultured	2006
[Effect of realgar on the gene expression profile of multiple myeloma cell line RPMI 8226]. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2006, Volume: 31, Issue:1 Topics: Arsenicals; Gene Expression Profiling; Humans; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Sulfides; Tumor Cells, Cultured	2006
[Effect of arsenic trioxide on bone marrow stromal cells of patients with multiple myeloma]. Zhongguo shi yan xue ye xue za zhi, 2006, Volume: 14, Issue:2 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Depression, Chemical; Humans; Interleukin-6; Multiple Myeloma; Oxides; Stromal Cells; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A	2006
Mechanism of arsenic trioxide inhibiting angiogenesis in multiple myeloma. Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2006, Volume: 26, Issue:1 Topics: Angiogenesis Inhibitors; Arsenic Trioxide; Arsenicals; Brain-Derived Neurotrophic Factor; Cell Line, Tumor; Dose-Response Relationship, Drug; Endothelial Cells; Humans; Multiple Myeloma; Neovascularization, Pathologic; Oxides; Receptor, trkB	2006
Sustained activation of c-jun-N-terminal kinase plays a critical role in arsenic trioxide-induced cell apoptosis in multiple myeloma cell lines. Cancer science, 2006, Volume: 97, Issue:6 Topics: Anisomycin; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Enzyme Activation; Enzyme Inhibitors; Flow Cytometry; Humans; JNK Mitogen-Activated Protein Kinases; Membrane Potentials; Mitochondria; Multiple Myeloma; Oxides; Protein Synthesis Inhibitors	2006
Gene expression profile of multiple myeloma cell line treated by realgar. Journal of experimental & clinical cancer research : CR, 2006, Volume: 25, Issue:2 Topics: Arsenicals; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Microarray Analysis; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfides; Tumor Cells, Cultured	2006
A patient with progressive multiple myeloma treated successfully with arsenic trioxide after allogeneic bone marrow transplantation. Acta haematologica, 2007, Volume: 117, Issue:2 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Combined Modality Therapy; Graft vs Host Disease; Humans; Male; Middle Aged; Multiple Myeloma; Oxides	2007
[n-MSP detection of p16 gene demethylation and transcription in human multiple myeloma U266 cell line induced by arsenic trioxide]. Zhongguo shi yan xue ye xue za zhi, 2007, Volume: 15, Issue:1 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Base Sequence; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; DNA Methyltransferase 3B; Genes, p16; Humans; Molecular Sequence Data; Multiple Myeloma; Oxides; Polymerase Chain Reaction; Promoter Regions, Genetic; RNA, Messenger; Transcription, Genetic	2007
Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid. British journal of haematology, 2007, Volume: 138, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Humans; Immunoglobulin G; Melphalan; Mice; Mice, SCID; Multiple Myeloma; Oxides; Pyrazines; Xenograft Model Antitumor Assays	2007
Arsenic metabolism in multiple myeloma and astrocytoma cells. Biological trace element research, 2007, Volume: 116, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Astrocytoma; Biotransformation; Bone Marrow Cells; Cell Line, Tumor; Chromatography, Ion Exchange; Humans; Models, Chemical; Multiple Myeloma; Oxides; Reactive Oxygen Species; Time Factors	2007
Refractory multiple myeloma treated with homoharringtonine: report of two cases. Annals of hematology, 2007, Volume: 86, Issue:12 Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carmustine; Cyclophosphamide; Dexamethasone; Doxorubicin; Harringtonines; Homoharringtonine; Humans; Male; Melphalan; Multiple Myeloma; Oxides; Prednisone; Remission Induction; Salvage Therapy; Thalidomide; Vincristine; Vindesine	2007
Effects of arsenic trioxide on voltage-dependent potassium channels and on cell proliferation of human multiple myeloma cells. Chinese medical journal, 2007, Jul-20, Volume: 120, Issue:14 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Multiple Myeloma; Oxides; Potassium Channel Blockers; Potassium Channels, Voltage-Gated	2007
[Mechanisms underlying the effect of arsenic trioxide on proliferation inhibition and apoptosis induction in myeloma cell line u266]. Zhongguo shi yan xue ye xue za zhi, 2007, Volume: 15, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Line, Tumor; Cell Proliferation; Humans; Multiple Myeloma; Oxides; RNA, Messenger; Telomerase	2007
[Effects of As2O3, dexamethasone and thalidomide on apoptosis and cytoplasmic [Ca2+] of myeloma cell line U266]. Zhongguo shi yan xue ye xue za zhi, 2007, Volume: 15, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Calcium; Cell Line, Tumor; Cytoplasm; Dexamethasone; Humans; Multiple Myeloma; Oxides; Thalidomide	2007
Analytical artefacts in the speciation of arsenic in clinical samples. Analytica chimica acta, 2008, Jan-21, Volume: 607, Issue:1 Topics: Arsenic Trioxide; Arsenicals; Artifacts; Chromatography, High Pressure Liquid; Humans; Leukemia, Promyelocytic, Acute; Mass Spectrometry; Multiple Myeloma; Oxides; Spectrometry, Fluorescence	2008
P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells. British journal of haematology, 2008, Volume: 140, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Imidazoles; Molecular Chaperones; Multiple Myeloma; Neoplasm Proteins; Oxides; p38 Mitogen-Activated Protein Kinases; Pyridines; Signal Transduction; Tumor Cells, Cultured; Up-Regulation	2008
Gene expression profile of multiple myeloma cell line treated by arsenic trioxide. Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2007, Volume: 27, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Gene Expression Profiling; Humans; Multiple Myeloma; Oxides; Tumor Cells, Cultured	2007
[Effect of arsenic trioxide combined with bortezomib on proliferation, apoptosis and beta-catenin level in myeloma cell lines]. Zhongguo shi yan xue ye xue za zhi, 2008, Volume: 16, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; beta Catenin; Boronic Acids; Bortezomib; Cell Proliferation; Drug Synergism; Humans; Multiple Myeloma; Oxides; Pyrazines; Tumor Cells, Cultured	2008
BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma. Blood, 2008, May-15, Volume: 111, Issue:10 Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Bcl-2-Like Protein 11; Cell Death; Cell Line, Tumor; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Multiple Myeloma; Oxides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2	2008
Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib. Leukemia research, 2008, Volume: 32, Issue:11 Topics: 2-Methoxyestradiol; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; beta Catenin; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Estradiol; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Oxides; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured	2008
Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer research, 1999, Mar-01, Volume: 59, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Cell Division; Cell Line; Cell Survival; Flow Cytometry; Fluorescent Antibody Technique, Indirect; Humans; Kinetics; Lymphocyte Activation; Melarsoprol; Multiple Myeloma; Neoplasm Proteins; Nuclear Proteins; Oxides; Plasma Cells; Promyelocytic Leukemia Protein; Transcription Factors; Tumor Suppressor Proteins	1999
Clinical trials referral resource. Clinical trials with arsenic trioxide. Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:2 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Female; Humans; Leukemia; Lymphoma; Multiple Myeloma; Neoplasms; Oxides; Urogenital Neoplasms; Uterine Cervical Neoplasms	2000
Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer research, 2000, Jun-01, Volume: 60, Issue:11 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Northern; Blotting, Western; Caspase 3; Caspases; Cell Cycle; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Inhibitory Concentration 50; Multiple Myeloma; Oxides; Precipitin Tests; Time Factors; Tumor Cells, Cultured	2000
Co-biomodulation with arsenic trioxide in multiple myeloma. Leukemia research, 2001, Volume: 25, Issue:3 Topics: Adjuvants, Immunologic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Humans; Killer Cells, Lymphokine-Activated; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Oxides	2001
Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As(2)O(3)) on myeloma cells. Leukemia research, 2001, Volume: 25, Issue:3 Topics: ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Antigens, CD; Antigens, Differentiation; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cytotoxicity, Immunologic; Dose-Response Relationship, Drug; Growth Inhibitors; Humans; Immunophenotyping; Intercellular Adhesion Molecule-1; Killer Cells, Lymphokine-Activated; Membrane Glycoproteins; Multiple Myeloma; NAD+ Nucleosidase; Oxides; Tumor Cells, Cultured	2001
Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood, 2001, Aug-01, Volume: 98, Issue:3 Topics: Acetylcysteine; Antineoplastic Agents; Antioxidants; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cell Death; Drug Synergism; Glutathione; Humans; Hydrogen Peroxide; Multiple Myeloma; Oxides; Plasma Cells; Superoxides; Tumor Cells, Cultured	2001
Arsenic trioxide induces multiple myeloma cell apoptosis via disruption of mitochondrial transmembrane potentials and activation of caspase-3. Chinese medical journal, 2001, Volume: 114, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Caspase 3; Caspases; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Membrane Potentials; Mitochondria; Multiple Myeloma; Oxides; Tretinoin; Tumor Cells, Cultured	2001
[Mechanisms of arsenic trioxide-induced apoptosis in myeloma cells]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2001, Volume: 23, Issue:3 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Division; Dithiothreitol; Drug Interactions; Humans; Interferon-alpha; Multiple Myeloma; Oxides; Tretinoin; Tumor Cells, Cultured	2001
Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state. Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspase 8; Caspase 9; Caspases; Cell Division; Dexamethasone; Drug Resistance, Neoplasm; Glutathione; Glutathione Transferase; Multiple Myeloma; Oxidation-Reduction; Oxides; Steroids; Time Factors; Tumor Cells, Cultured	2002
Sedimentation analysis of a papain-digested human multiple myeloma gamma-G-globulin. The Journal of biological chemistry, 1966, Jun-25, Volume: 241, Issue:12 Topics: Arsenicals; Buffers; Chemical Phenomena; Chemistry, Physical; Chromatography, Gel; gamma-Globulins; Humans; Multiple Myeloma; Papain; Ultracentrifugation	1966
Lack of antibody activity in human myeloma proteins. Journal of immunology (Baltimore, Md. : 1950), 1971, Volume: 107, Issue:2 Topics: Antibodies; Antigens, Bacterial; Arsenicals; Azo Compounds; Benzene Derivatives; Dinitrophenols; Fluorescent Antibody Technique; Haptens; Humans; Immunodiffusion; Multiple Myeloma; Mycoplasma; Naphthalenes; Neoplasm Proteins; Polysaccharides, Bacterial; Pyridinium Compounds; Quaternary Ammonium Compounds; Streptococcus pneumoniae	1971
[Therapy of hemoblastosis. I. Elements of cytostatic and symptomatic therapy]. Giornale di clinica medica, 1966, Volume: 47, Issue:8 Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Arsenicals; Colchicine; Hodgkin Disease; Humans; Hydrazines; Immunosuppressive Agents; Leukemia, Lymphoid; Leukemia, Myeloid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Multiple Myeloma	1966
NEPHROCUTANEOUS SYNDROMES. Southern medical journal, 1964, Volume: 57 Topics: Amyloidosis; Anemia; Anemia, Sickle Cell; Angiokeratoma; Arachnodactyly; Arsenic; Blood Protein Disorders; Collagen Diseases; Dermatology; Drug Hypersensitivity; Ehlers-Danlos Syndrome; Glomerulonephritis; Humans; Kidney Diseases; Leukemia; Lupus Erythematosus, Systemic; Marfan Syndrome; Metabolic Diseases; Multiple Myeloma; Neurofibromatoses; Pseudoxanthoma Elasticum; Purpura; Pyelonephritis; Skin Neoplasms; Toxicology; Tuberous Sclerosis; Vascular Diseases	1964
RIP kinase is involved in arsenic-induced apoptosis in multiple myeloma cells. Apoptosis : an international journal on programmed cell death, 2004, Volume: 9, Issue:5 Topics: Apoptosis; Arsenic; Caspase 3; Caspases; Cell Division; Cell Line, Tumor; Cell Survival; Enzyme Activation; Humans; Melarsoprol; Multiple Myeloma; NF-kappa B	2004